Epacadostat Plus Pembrolizumab Shows Early Promise in Advanced RCC
Epacadostat plus pembrolizumab yielded “encouraging response outcomes” among patients with 0 or 1 prior lines of therapy for advanced renal cell carcinoma.
16-Gene Recurrence Score for High-Risk RCC Offers Prognostic Value
Analysis from a phase III trial confirmed the prognostic value of a 16-gene recurrence score in patients with high-risk renal cell carcinoma undergoing adjuvant sunitinib therapy.
Pazopanib Not Recommended as Adjuvant Therapy of Locally Advanced RCC
Pazopanib 600 mg daily as adjuvant therapy did not prolong disease-free survival for patients with locally advanced renal cell carcinoma.
Pembrolizumab Plus Pazopanib Is Not Safe for Patients With RCC
Liver toxicity precludes development of pembrolizumab plus pazopanib immunotherapy for patients with advanced renal cell carcinoma.
First-Line Avelumab/Axitinib Shows Early Antitumor Activity in mRCC
Despite high rates of toxicity, a first-line tyrosine kinase inhibitor/immunotherapy combination exhibits promising antitumor activity in metastatic renal cell carcinoma.
Biomarkers Predict RCC Treatment Outcomes
Plasma levels of HGF, BAP1 and PBRM1 gene mutation status, and angiogenesis gene expression are promising predictive biomarkers for survival in RCC patients.
Clinicians Must Tailor Treatment for Metastatic RCC
In this interview we discuss decision making in the treatment of metastatic renal cell carcinoma.
Kidney Cancer Highlights of 2016
This slideshow takes a look at some of the top kidney cancer news of 2016, including FDA approvals, survival disparities, surgical approaches, and more.
Oncology Drug Snapshot: Axitinib (Inlyta)
This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
By clicking Accept, you agree to become a member of the UBM Medica Community.